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Methods: oRIGINAL ARtICLe
optimization of scAAVIL-1ra In Vitro and In Vivo to 
 deliver high Levels of therapeutic Protein for  
treatment of osteoarthritis
Laurie R Goodrich1, Jennifer N Phillips1, C Wayne McIlwraith1, Stacey B Foti2, Joshua C Grieger2, Steven J Gray2 and R Jude Samulski2
Osteoarthritis (OA) affects over 40 million people annually. We evaluated interleukin-1 receptor antagonist (IL-1ra) gene 
transfer in an equine model based on IL-1ra protein therapy which inhibits inflammation through blocking IL-1. Using the 
self-complementary adeno-associated virus (scAAV)IL-1ra equine gene as a starting construct, we optimized the transgene 
cassette by analyzing promoters (cytomegalovirus (CMV) versus chicken β-actin hybrid (CBh)), coding sequences (optimized 
versus unoptimized), vector capsid (serotype 2 versus chimeric capsid), and biological activity in vitro. AAV serotypes 2 and 
2.5 CMV scAAVoptIL-1ra were tested in equine joints. We evaluated two doses of scAAVIL-1ra, scAAVGFP, and saline. We 
developed a novel endoscopy procedure and confirmed vector-derived transgene expression (GFP) in chondrocytes 6 months 
post-injection. AAVIL-1ra therapeutic protein levels were 200–800 ng/ml of synovial fluid over 23 and 186 days, respectively. 
No evidence of intra-articular toxicity was detected and no vector genomes were found in contralateral joints based on GFP 
fluorescence microscopy and quantitative PCR. Finally, we assayed vector-derived IL-1ra activity based on functional assays 
which supported anti-inflammatory activity of our protein. These studies represent the first large animal intra-articular gene 
transfer approach with a therapeutic gene using scAAV and demonstrate high levels of protein production over extended time 
supporting further clinical investigation using scAAV gene therapy for OA.
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Introduction
Osteoarthritis (OA) is a progressive and debilitating joint dis-
ease for which there is no cure. It affects over 40 million people 
annually and is responsible for tremendous financial burdens 
on health systems especially in societies with growing popu-
lations of elderly and obese individuals.1 Furthermore, the 
disease negatively affects younger, active individuals that par-
ticipate in high demand sports and suffer from post-traumatic 
arthritis or overuse syndrome.2 The proinflammatory cytokine 
primarily responsible for many of the pathological features 
of OA is interleukin-1β (IL-1β).3 IL-1β has been found to be 
upregulated in synovial tissues and cartilage and a strong cor-
relation has been consistently found with levels of IL-1β and 
osteoarthritic changes such as cartilage degeneration and 
presence of inflammation.1 Initially, treatment for OA consisted 
of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 
inhibitors, which reduced symptoms of pain and inflammation, 
caused by IL-1β but did not deter progression of OA.4,5 In addi-
tion, with prolonged use, these drugs can be associated with 
gastrointestinal disorders and cardiovascular ischemic events 
that can sometimes even lead to the demise of the patient.6
In the last two decades, researchers have sought to explore 
pharmaceuticals that can not only control symptoms of OA 
but also slow the progression and even prevent or stop degen-
eration of the joint thus bypassing the need of inevitable joint 
replacement. Although drugs such as hyaluronan and glu-
cosamine/chondroitin sulfate have been somewhat disease 
modifying, they have not alleviated symptoms as effectively 
as originally forecasted.7–11 A logical target for blocking effects 
of IL-1β is the molecule IL-1 receptor antagonist (IL-1ra). This 
molecule is the natural inhibitor of IL-1β and competes with 
IL-1β for occupancy of the IL-1 cell surface receptors but can-
not initiate cellular signals when bound to these receptors.3 
Studies have revealed that the IL-1ra concentration is low in 
inflamed joints and a level of tenfold to 1,000-fold excess of 
IL-1ra over IL-1β is required to effectively block all of the avail-
able IL-1 receptors enough to inhibit joint degeneration.12–14 
Autologous-conditioned serum, harvested from patient’s 
blood, is a biological treatment that has high levels of con-
stitutive IL-1ra concentrations and has been met with vary-
ing degrees of success in both humans and horses suffering 
from OA.15,16 One reason may be that levels of IL-1ra protein 
are not high enough and not sustained for periods required to 
inhibit ongoing inflammation.16
Gene transfer using viral vectors to initiate therapeutic 
levels of IL-1ra or growth factors in joints is a promising 
approach and “proof of concept” in delivering therapeutic 
genes to joints by direct in vivo injection.17–21 Various viral 
vectors have been utilized for intra-articular gene therapy 
including adenovirus, retrovirus, lentivirus and adeno-asso-
ciated virus (AAV).17,19,22,23 Adenoviral vectors have resulted 
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in significant elevations of protein (IL-1ra, insulin-like growth 
factor-I) when injected intra-articularly; however, levels 
only remain elevated for 14–21 days and adenoviral vec-
tors themselves can cause significant inflammation due to 
their immunogenic stimulation.17,18,24 Retroviral vectors have 
also significantly increased protein levels, however; these 
vectors do not efficiently transduce nondividing cells and 
therefore are less suited for joint tissues where cell turn-
over is low.22 Lentiviral vectors based on integration into 
the chromosome, offers the potential of long-term expres-
sion for OA; however, when injected into the knee joints of 
immunocompetent rats, the results demonstrate a sharp 
decrease in protein expression at ~20 days and therefore 
may not be the vector of choice for long-term protein pro-
duction for direct intra-articular injections.23 AAV has been 
studied and validated to result in significant elevations in 
protein expression.19,25 Kay et al. compared single-stranded 
AAV to self-complementary AAV (scAAV) and reported a 
25-fold greater transgene expression level for scAAV con-
firming that second strand DNA synthesis can be a major 
impediment to transduction efficiency in the joint.19 Further-
more, in Kay et al. scAAV not only resulted in dramatically 
increased transduction efficiency when compared with the 
single-stranded AAV but also did not reveal a difference in 
transduction between normal and inflamed articular environ-
ments suggesting that scAAV may be an appropriate vector 
in OA. Suitability of scAAV vectors intra-articularly was fur-
ther confirmed in equine joints when transduction efficiency 
of AdGFP, rAAV, and scAAV were compared over a period 
of 8 weeks.26 Goodrich et al. compared scAAV serotypes 
in synoviocytes and chondrocytes in vitro and revealed the 
importance of serotype affinity in that significant differences 
existed in transduction efficiencies in both synoviocytes and 
chondrocytes which are the main cell types in joints.27 Sero-
type 6 was better in chondrocytes and serotype 3 in synovi-
ocytes whereas serotype 2 was best in both chondrocytes 
and synoviocytes.27 This was also revealed by Sun et al. 
where various serotypes of scAAVFIX resulted in differing 
factor IX levels in the joints of mice.28
In addition to varying serotype efficiencies intra-articularly, 
various promoters may also change protein production.29 
Few studies have been performed to investigate optimal use 
of promoters to enhance transgene expression intra-articu-
larly but existing data suggest different promoters may play 
an important role in maximizing protein expression and vari-
ability exists with different promoters.30,31 Furthermore, opti-
mization of transgene cassette often enhances therapeutic 
output of protein through favoring codon usage to exploit 
amino acyl-transfer RNA molecules that are most abundant 
in mammalian cells.29
Regardless of promising results seen in vitro, protein 
expression in cell culture may not always represent protein 
expression in vivo due to unforeseen immunity, transduction 
efficiency, and species differences. Since gene therapeutic 
vectors targeted for OA should produce protein levels for 
long periods of time (over 4 months), the objective of this 
study was to optimize variables of our scAAV vector such as 
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Figure 1 Plasmid design and protein production. (a) Vector 
constructs of the non-optimized (top) and optimized (bottom) 
CBhEqIL-1ra-pTRs-ks plasmids (left) and the CMVEqIL-1ra-pTRs-
ks plasmids (right). Specific base pair sequence changes were 
made in the optimized IL-1ra gene (without affecting the protein 
sequence) so that the protein would be produced more efficiently by 
the scAAV construct. (b) IL-1ra production in transduced 293 cells. 
IL-1ra production was assessed in 293 cells transduced with 2 μg/
cm of optimized and non-optimized equine IL-1ra plasmid constructs. 
















































Figure 2 Promoter effects on IL-1ra production in transduced 
chondrocytes or synoviocytes. (a,b) IL-1ra production in 
(a) equine chondrocytes transduced with Eq-opt-IL-1ra-scAAV2 
and (b) equine synoviocytes transduced with Eq-opt-IL-1ra-scAAV2 
containing a CMV (diagonal lines) or CBh (solid bar) promoter. CMV, 
cytomegalovirus; IL, interleukin; vpc, viral particles per cell.
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promoter and transgene, first in vitro and then, using our opti-
mized promoter and transgene, compare our two best scAAV 
serotypes in vivo to explore the application of scAAV gene 
therapy in an equine model.11,18,32 We hypothesized that we 
could optimize promoter and transgene in vitro and test this 
vector in vivo to determine efficacy of transgene production 
in the equine joint. This is the first study to report significant 
protein elevations for up to 6 months using scAAV in large 
animal (equine) joints.
Results
optimization of IL-1ra cassette and CMV and CBh 
promoters
An optimized equine IL-1ra (OptEqIL-1ra) gene sequence 
was designed and produced by GeneArt to produce greater 
amounts of protein due to more efficient transcription and 
translation. Essentially, specific nucleotide sequences were 
altered so they produced the same protein, but minimized the 
expression of sequence repeats, splice sites, and secondary 
structures as this technology has been shown to be success-
ful in clinical trials.33 OptEqIL-1ra and non-optimized EqIL-
1ra genes were cloned into mammalian expression vectors 
(pTRs-ks) containing a cytomegalovirus (CMV) or chicken 
β-actin hybrid (CBh) promoter (Figure 1a), and evaluated 
for protein production in transfected 293 cells. The optimized 
constructs produced higher levels of IL-1ra than their unop-
timized (wild-type) counterparts, which had threefold higher 
(Eq-opt-CBhIL-1ra) and 27-fold higher (Eq-opt-CMVIL-1ra) 
IL-1ra protein levels, respectively (Figure 1b).
CMV and CBh-Eq-optIL-1ra-pTRs-ks plasmids were pack-
aged into a scAAV2 construct, and evaluated for protein 
production and functionality in equine chondrocytes and 
synoviocytes. Transductions were carried out with 8,000 viral 
genomes per cell based on a previous in vitro study com-
paring dosages of viral vector per cell.27 CMVEq-opt-IL-1-
ra-scAAV2 and CBhEq-opt-IL-ra-scAAV2 produced similar 
levels of IL-1ra protein in chondrocytes (17 ng/ml) D10 post-
transduction (Figure 2a), while CMVEq-opt-IL-1ra-scAAV2 
produced threefold higher (24 versus 8 ng) levels of CBhEq-
opt-IL-1ra-scAAV2 in synoviocytes (Figure 2b). Because 
both the synovium and cartilage are targets for gene ther-
apy within the joint, the CMV promoter was chosen for use 
in vivo as it efficiently enhanced protein production in both 
tissues comparably whereas the CBh promoter had lower 
protein expression in synoviocytes. Functionally, there was 
no significant difference between constructs with the two dif-
ferent promoters in their ability to minimize the inflammatory 
response of cultured cells to rIL-1β stimulation. CMV-Eq-opt-
IL-1ra-scAAV2 reduced the inflammatory response of syn-
oviocytes by 88% whereas the CBh-Eq-opt-IL-1ra-scAAV2 
construct reduced the response by 82% (Figure 3) suggest-
ing we reached saturation.
optimization of serotype and dose in vivo
In a previous study, we evaluated serotypes 1–6, and 8 
using an scAAVeGFP cassette and the results indicated 
that serotype 2 scAAVGFP was the most efficient for trans-
duction of equine chondrocytes and synoviocytes.27 Com-
parisons of scAAV2 and 2.5 in this study revealed similar 
transduction efficiencies (data not shown). For the in vivo 
pilot study, saline, serotype 2 or S2.5scAAVCMVGFP was 
administered intra-articularly and other joints received sero-
type 2 or S2.5scAAVeq-opt-IL-1ra constructs administered 
at 5 × 1012 or 5 × 1013 viral genomes per joint (Figure 4a). 
Following injections, horses were measured for lameness, 
joint effusion or pain on flexion/manipulation of joints until 
termination. None of these clinical parameters indicated 
adverse events.
Circulating levels of IL-1ra in the serum from both horses 
was minimal (<1 ng/ml) and primarily detected in samples 
taken between D14 and D56 (data not shown). Analysis of 
the synovial fluid samples in Horse 2 (horse used for short-
term study) revealed high levels (200–1,600 ng/ml) of IL-1ra 
in the S2- and S2.5scAAVIL-1ra–dosed joints for all time 
points examined beyond D0 (Figure 4a,b), suggesting equal 
transduction efficiencies of S2 and S2.5 in vivo for the dose 
tested. Fluid cytology analysis revealed that there was an ini-
tial spike of 40,000 WBC (cells/μl) in the scAAVGFP-injected 
joint (left carpus) that quickly returned to baseline levels by 
D21. Differential analysis revealed that the majority of WBC’s 
consisted of lymphocytes and less commonly neutrophils. 
Interestingly, the joints injected with serotype 2, serotype 2.5 
scAAVeq-opt-IL-1ra or saline had only a brief and minor rise 
(<2,000 cells/μl) in WBC.
The left carpus (saline injected) had a brief rise in IL-1ra 
protein most likely due to a well-published “contralateral effect” 























































Figure 3 Promoter effects on inhibition of PGe2. (a,b) PGE2 
inhibition in (a) Eq-opt-IL-1ra-scAAV–trans duced chondrocytes and 
PGE2 inhibition in (b) Eq-opt-IL-1ra-scAAV–transduced synoviocytes. 
rIL-1β was used to stimulate cells 2 days post-transduction. 
Assessments were made 6 days post-transduction using a PGE2 
ELISA kit. CMV, cytomegalovirus; IL, interleukin; PGE2, prostaglandin 
E2; scAAV, self-complementary adeno-associated virus.
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rise in the contralateral joint. This effect was not observed 
in the metacarpophalangeal joints of Horse 2. Horse 1 
(horse used for long-term study) also had high levels (200–
1,800 ng/ml) of IL-1ra detected beginning at D14 post-induc-
tion and continuing to D182 (Figure 4c,d). More specifically, 
levels of IL-1ra varied between 400–1,200 ng/ml from D14 
to D77 and then had an overall downward trend from D91 
to D126 but continued to be above 200 ng/ml at D182. WBC 
count in all joints except saline had a mild and brief rise 
(<4,000 cells) but quickly returned to baseline by D21.
The carpal joints of Horse 1 were arthroscopically exam-
ined following euthanasia (supplementary Video s1a,b). The 
arthroscope has a fluorescent filter in which fluorescing cells 
can be imaged within the joint. Several areas of cartilage surface 
had fluorescent cells (chondrocytes) in the scAAVGFP-injected 
joint whereas no cartilage surface in the scAAV-Eq-opt-IL-1-
ra–injected joint exhibited fluorescent cells (supplemen-
tary Video s1). Cartilage biopsies were performed from 
fluorescing areas of cartilage (viewed arthroscopically) and 
subsequently viewed with the fluorescent microscope which 
confirmed intense fluorescing chondrocytes (Figure 5d,e). 
Synovial tissue from both scAAVGFP- and scAAV-Opt-eq-
IL-1ra–injected joints did not fluoresce in the horse that was 
arthroscopically examined. Based on fluorescent microscopy 
of the synovium (Horse 2) or arthroscopy (Horse 1) it appears 
that synovial tissue fluorescence diminishes with the turnover 
of synovial cells over time.
testing functionality of therapeutic protein from synovial 
fluid samples
Synovial fluid samples from injected joints were assessed 
for their ability to minimize the inflammatory response to cul-
tured synoviocytes stimulated with 10 ng/ml of equine rIL-1β 
 (Figure 6). Four time points were randomly selected from 
Horse 1 and added to synoviocytes at equal volumes simul-
taneously with equine rIL-1β–stimulated media. Synovial fluid 
samples collected from the IL-1ra–dosed joints consistently 
minimized the inflammatory response to the equine rIL-1β sug-
gesting that the level of IL-1ra within the joint fluid decreased 
IL1-β–induced inflammation. As expected, the synovial fluid 
from the saline-injected joints had minimal decrease or an 
elevation in IL-1β.
Eq-Opt-IL-1ra-scAAV2
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Right carpus synovial fluid IL-1ra production and WBC
in horse 2 (Eq-opt-IL-1ra-scAAV2, 5 × 1013 vp)
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Right metacarpophalangeal synovial fluid IL-1ra
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Left carpus synovial fluid IL-1ra production and WBC
in horse 2 (GFPscAAV2, 5 × 1013 vp)
Right carpus synovial fluid IL-1ra production and WBC
in horse 1 (GFPscAAV2, 5 × 1013 vp)
Left carpus synovial fluid IL-1ra production and WBC
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Figure 4 effects of serotype and dose on in vivo testing of  eq-opt-IL-1ra-scAAV and GFPscAAV. (a) Clinical design for the dosing of 
Horse 2 (horse used for short-term administration). The blue circles correspond to the carpal joints, and the green circles correspond to the 
metacarpophalangeal joints. scAAV constructs were given at specific concentrations per joint, whereas 5 ml of saline was administered into 
the control joint. (b) IL-1ra expression (left y-axis) in bars and WBC counts (right y-axis) in line graph (cells/μl) in the synovial fluid of the carpus 
and metacarpophalangeal joints of Horse 2. Each joint is graphed separately over time. IL-1ra levels were assessed with an equine IL-1ra 
ELISA kit. Note: the WBC numbers on the top right graph are higher due to a higher WBC count in that joint. WBC counts were not determined 
at D23. (c) Clinical design for the dosing of Horse 1 (horse used for long-term study). The blue circles correspond to the carpal joints, and 
the green circles correspond to the metacarpal phalangeal joints. scAAV constructs were given at specific concentrations per joint, whereas 
5 ml of saline was administered into the control joint. (d) IL-1ra expression (left y-axis) and WBC counts (cells/μl) (right y-axis) in the synovial 
fluid of the carpus and metacarpophalangeal joints of Horse 1. Each joint is graphed separately over time. GFP, green fluorescent protein; 
IL, interleukin; scAAV, self-complementary adeno-associated virus; vp, viral particles.
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distribution of viral genomes in joints and body tissues 
and histology of joint tissues
Tissue samples were collected at necropsy from both ani-
mals to assess the biodistribution of scAAV-Eq-opt-IL-1ra viral 
genomes. Quantitative PCR analysis revealed a higher num-
ber of viral genomes (specifically detecting the optimized IL-1ra 
transgene) detected in cartilage samples than synovial samples 
for both animals (Figure 5a–c). No vector genomes were found 
in the saline joints and minimal to no scAAV-Eq-opt-IL-1ra vec-
tor genomes were found in the scAAVGFP-injected joints.
Fluorescent microscopy of Horse 1 revealed a similar 
trend to the fluorescent arthroscopic assessment in that 
the scAAVGFP-dosed joint revealed intensely fluoresc-
ing  chondrocytes within the cartilage and no fluorescing 
 synoviocytes within synovium (183 days following injec-
tion) (Figure 5d). For Horse 2 both cartilage and synovium 
taken from the scAAVGFP-dosed joint (at day 23) were flu-
orescent (Figure 5e) again supporting published data that 
chondrocytes have an extended half-life compared with 
synoviocytes.34
Figure 5 Analysis of vector genomes and detection of GFP fluorescent cells. (a) Distribution of IL-1ra viral genomes per cell for 
Horse 1 and (b) distribution of viral genomes per cell for Horse 2 carpus and metacarpophalangeal tissue samples. (c) Equine-optimized 
biodistribution of IL-1ra viral genomes per cell for tissues collected at the termination of the study. (d) Horse 1 carpal joint and (e) Horse 
2 carpal joint. GFP expression in S2- and S2.5scAAVGFP-injected carpal joints. Metacarpophalangeal joints were not shown because 
they were not expressive of GFP (as they were injected with scAAVIL-1ra or saline). Images were captured using ×100 magnification, with 
a FITC fluorescent filter cube (excitation of 495 nm and emission of 521 nm). FITC, fluorescein isothiocyanate; GFP, green fluorescent 
protein; IL, interleukin; LMCP, left metacarpal phalangeal joint; RMCP, right metacarpal phalangeal joint; scAAV, self-complementary adeno-
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No evidence of intra-articular toxicity was determined 
in observation and scoring of synovium and cartilage. 
Finally, no significant differences were found between joints 
injected with scAAVGFP, scAAV-Eq-opt-IL-1β or saline in 
terms of synovial thickening and hyperplasia and cartilage 
matrix loss.
discussion
The results of this study reveal the first successful demon-
stration of dramatic increases in the therapeutic protein, 
IL-1ra, for extended periods of time in large animal (equine) 
joints. These data are important as they suggest that scAAV 
gene therapy will be efficient in transducing joint tissues for 
extended periods of time without causing intra-articular tox-
icity in the equine model, a model that is commonly used 
to mimic OA in people.18,35 Others have demonstrated effi-
cient transduction of scAAV in rats,36 rabbits,19 and horses26 
although in those studies extended long-term production of 
protein was not longer than 8 weeks. Gouze et al. elegantly 
demonstrated that synovial tissue is efficiently transduced 
by viral vectors but suggested that synoviocytes may not be 
ideal gene therapy targets for long-term protein production 
due to turnover of synoviocytes.34 In that study, synovio-
cytes efficiently transduced with lentiviral vectors were all 
but absent by day 162 and authors suggested that neighbor-
ing ligaments, tendons, and capsular tissues may be more 
appropriate targets due to reduced cellular turnover.34 Our 
study suggests that the stable and low-dividing chondrocytes 
are ideal targets and will efficiently produce therapeutic pro-
tein for up to 183 days (final test day measured, Figure 4d). 
Although the protein production had a downward trend from 
day 0 to day 182, the measured protein is consistent with 
therapeutic amounts in the joints through the final time point 
of synovial fluid harvest. Fluorescent arthroscopic video of 
the scAAV injected joint at 6 months had stably transduced 
cartilage and when biopsies of this tissue were viewed with 
the fluorescent microscope, large numbers of chondrocytes 
were fluorescing, confirming this observation. From our 
analysis, we would conclude that both chondrocytes and 
synoviocytes are targets for AAV gene transfer, but long-term 
transgene expression will predominantly utilize chondrocytes 
as target tissue.
Many studies highlight the importance of immune compat-
ibility between vector, transgene, and host.19,23,34,37 Consis-
tently, expression of a gene of cross-species origin is quickly 
extinguished regardless of gene delivery with a vector that 
expresses viral proteins at low levels.34 We sought to not only 
use the equine transgene in our equine model but to optimize 
the transgene to more efficiently produce protein potentially 
allowing for a lower effective dose of vector intra-articularly. 
In past studies, transgene optimization has resulted in much 
greater protein production and has shown promise in gene 
therapy strategies in which more efficient translation of pro-
tein is required.29,33 The process of optimizing cDNA results 
in more efficient transcription due to the elimination of RNA 
secondary structures and enhanced translation commensu-
rate with the abundance of the transfer RNA within that spe-
cies. In addition, promoter optimization is another approach 
to maximizing protein production and reducing the amount 
of vector administered. Previous studies have compared the 
CMV and CBA promoters in mammalian cells.38,39 A hybrid 
of the CBA promoter (CBh) was developed which provided 
a smaller base pair segment and resulted in a more robust 
protein expression than CMV in neuronal cells.40 It was our 
goal to determine whether this was also the case in the cells 
of joint tissues. Our results revealed that CMV still appears to 
be the better promoter in joint tissues. Furthermore, the CMV 
promoter combined with the optimized transgene resulted 
in optimal protein production of equine IL-1ra, respectively 
 (Figures 1b,2).
Our group previously evaluated serotype affinity and vec-
tor dose in vitro using scAAVGFP and, in that study, AAV2 
was consistently the most efficient at transducing both syn-
oviocytes and chondrocytes.27 When we began testing the 
optimized transgene and various promoters in the present 
study we did not have access to serotype 2.5, an enhanced 
chimeric vector recently tested in a clinical trial for Duch-
enne muscular dystrophy, however, following optimization of 

























































Figure 6 IL-1β inhibition using synovial fluid of transduced joints. (a) IL-1β expression in stimulated synoviocytes treated with Horse 
1 synovial fluid and (b) IL-1β expression in stimulated synoviocytes treated with Horse 2 synovial fluid. Functional assessment of rIL-1β–
stimulated synoviocytes treated with D14 synovial fluid from Horse 2 and D98 synovial fluid for Horse 1. The amount of IL-1ra present in 
the synovial fluid for each joint is indicated in parentheses. The amount of inhibition or increase in IL-1β levels are indicated with arrows 
and percentages (of decrease). Samples were assessed with an equine IL-1β ELISA kit. ctrl, control; IL, interleukin; LMCP, left metacarpal 
phalangeal joint; RMCP, right metacarpal phalangeal joint; scAAV, self-complementary adeno-associated virus.
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2 and 2.5 in vitro in both synoviocytes and chondrocytes. 
Since they were comparable in transduction efficiency, we 
sought to compare them in equine joints using our optimized 
transgene and promoter. No differences existed in IL-1ra lev-
els between joints injected with serotype 2 and 2.5 chimeric 
capsid (Figure 4). Both serotypes efficiently transduced the 
joint tissues and resulted in high levels of protein production 
of over 23 days and 6 months, respectively. The dosages 
used in this study were chosen based on a previous study in 
which rAAV2-TNFR:Fc was administered to human joints in 
a phase 1/2 study to determine the safety and tolerability of 
repeat injections intra-articularly.41 In that study, patients had 
minimal complications and demonstrated good response to 
the intra-articular gene therapy.41 In the current study, horses 
did not demonstrate lameness, joint swelling or pain on joint 
manipulation for the duration of the study. WBC rose in one 
joint of Horse 2 receiving S2scAAVGFP but quickly returned 
to baseline by day 21 post-injection. Three joints in Horse 1 
had very mild elevations of WBC and those joints received 
scAAVGFP or scAAV-Eq-opt-IL-1ra. Differential analysis of 
white cell elevations consisted of mononuclear cells, spe-
cifically lymphocytes. Neutrophils may have also increased 
at earlier time points (before 14 days), however, we did not 
harvest synovial fluid earlier than this time point so it is not 
known whether a different type of white cell increased as well. 
No differences were detected in IL-1ra protein levels between 
dosages of 5 × 1013 and 5 × 1012 viral particle. This suggests 
that a saturation effect of the scAAV vector constructs was 
attained at both doses and that lower doses may be just as 
efficacious (studies ongoing). Further studies are ongoing to 
determine how lower dosages may affect protein production.
Consistent with other studies utilizing gene therapy vectors, 
we observed an interesting rise in IL-1ra in the carpal joint 
contralateral to the carpal joint injected with scAAV-Eq-opt-
IL-1ra.42–46 As in previous publications reporting the “contral-
ateral effect” we believe the protein in the contralateral joint to 
be a product of the transgene of the joint injected with scEq-
opt-IL-1ra and not a product of vector migration to the con-
tralateral joint since no vector genomes were found in either 
the synovium or cartilage of the joint not receiving scAAV 
vector, but positive for low level IL-1ra protein (F igure 5a). 
Furthermore, when synovium and cartilage were examined 
from all joints injected with either scAAVGFP or scAAVEq-
opt-IL-1ra, only the joints injected with scAAVGFP had joint 
tissues that fluoresced (Figure 5) confirming that vector 
genomes probably do not migrate to the contralateral joints. 
Synovial elevations of IL-1ra in the scAAVGFP-injected joint 
were also most likely not from a rise in the serum levels due to 
a negligible increase of IL-1ra protein of <1 ng/ml measured 
at all time points. In a study by Ghivizzani et al.,where ade-
noviral vectors were tracked following joint injection, authors 
found that when knee joints of rabbits were injected with an 
adenoviral vector encoding luciferase (AdLuc), a percentage 
of the leukocytes present in the joint at the time of AdLuc 
injection were transduced and then migrated to the lymph 
node of the contralateral limb and subsequently were found 
in the contralateral joint.42 This contralateral effect was also 
seen in Lechman et al. where in addition to transduced leuko-
cytes, transduced immature dendritic cells and macrophages 
were also suspected of migrating from the injected joint to 
the contralateral joint by way of the lymph node circulation.46 
Leucocytes, macrophages, and immature dendritic cells 
were not tracked in the current study, however; this method 
of elevated protein could be responsible for a contralateral 
effect seen in Horse 2.
It was interesting that we were able to detect vector 
genomes in some of the tissues (cartilage) of joints injected 
with scAAVEq-opt-IL-1ra but not others (Figure 5a,b). We 
believe this may be due to variability where transduction 
occurs in the joint and whether these areas were harvested 
at tissue collection. As seen in the arthroscopy videos of the 
joint injected with scAAVGFP, area of cartilage transduction 
varied (supplementary Video s1a). Although the harvest 
sites of cartilage and synovium were consistent at necropsy, 
areas of the joint transduction could have varied enough to 
result in differing amounts of vector genomes measured.
This is the first intra-articular gene therapy study to demon-
strate arthroscopic confirmation of transduced joint tissues. 
The technique is straightforward and easy to use although 
one must keep in mind that some amount of autofluores-
cence of the cartilage and synovial tissues exist. We believe 
this may be an extremely valuable tool to document tissue 
transduction intra-articularly without disturbing joint tissues 
(performing a biopsy) throughout gene therapy trials.
Functionality of the IL-1ra protein found in the synovial flu-
ids was proven by stimulating synoviocytes with IL-1β and 
then measuring the ability of the synovial fluid to reduce 
inflammation. We chose timepoints of when the synovial fluid 
was collected (day 14 and day 98) based on whether we had 
enough fluid to perform the experiment. Reductions in IL-1β 
resulted whenever synovial fluid containing IL-1ra was placed 
on IL-1β–stimulated synoviocytes although percent reductions 
were not proportional. This may be due to the fact that syn-
ovial fluid itself has anti-inflammatory properties and therefore 
proportional decreases in IL-1β may be difficult to measure.
These data are the first to reveal that scAAV gene therapy 
may be a realistic option to cause high levels of therapeutic 
protein in the joint to ultimately treat OA in a large animal model 
that is commonly used to mimic OA in humans. The information 
gained from this study has wide impact on gene therapy for OA 
as it reveals that cartilage is stably transduced in situ and can 
produce significant amounts of therapeutic proteins for periods 
of at least 6 months adding to and extending information gained 
from short-term studies in rat, rabbit, dogs, and horse.19,21,26,28 
Ishihara et al., attempted to induce high therapeutic levels of 
BMP-2 in equine joints using scAAVBMP-2 but were not able 
to detect appreciable amounts of protein.47 Investigators of that 
study hypothesized that synovial fluid may have had an inhibi-
tory effect, however; this issue was not borne out in the current 
study. Regardless, our results demonstrate that (i) optimized 
promoter, (ii) transgene, and (iii) capsid tested first in vitro con-
veyed to long-term and high level efficacy of transgene pro-
duction in the equine joint. This study strongly suggests that 
further investigation of scAAVIL1-ra gene therapy to treat OA 
in large animal models is warranted.
Materials and methods
Gene cloning. An optimized sequence for the equine IL-1ra 
gene in a non-expression vector was purchased from GeneArt 
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(Invitrogen, Carlsbad, CA). The optimized sequence was 
generated from software, GeneOptimizer (Life Technologies, 
Grand Island, NY), which provides algorithms which optimize 
codon usage in a particular species to enhance protein pro-
duction. The optimized or unoptimized (wild-type) equine IL-
1ra gene was removed from the non-expression vector using 
NotI and AgeI restriction enzyme sites (NEB, Ipswich, MA), 
and ligated into a pTRs-ks mammalian expression vector 
obtained from the UNC Vector Core (Chapel Hill, NC) con-
taining either a CMV or CBh promoter.40,48 Ligations were 
performed using T4 Ligase as per manufacturer’s instruc-
tions (NEB). Constructs were validated by DNA sequencing 
and absence of mismatches were confirmed.
Plasmid and virus evaluation. pTRs-ks-IL-1ra plasmids were 
evaluated in 293 cells to ensure that the vector would pro-
duce detectable amounts of IL-1ra protein; 293 cells were 
plated to 60% confluency and equilibrated for 24 hours in 
Dulbecco’s modified Eagle’s medium (Invitrogen) containing 
10% fetal bovine serum (Sigma-Aldrich, St Louis, MO), 1X 
penicillin/streptomycin, and 1 N HEPES (Invitrogen). Cells 
were transfected with 2 μg/cm2 of plasmid DNA for 24 hours 
using JetPei transfection reagent (Polyplus, New York, NY). 
Medium was collected and evaluated with a mouse IL-1ra 
ELISA (R&D Systems, Minneapolis, MN).
scAAV expressing GFP and serotypes 2 and 2.5 were 
evaluated to determine which serotype had the highest trans-
duction efficiency in equine chondrocytes and synoviocytes.
Plasmids were transferred into scAAV2 and scAAV2.5 con-
structs (UNC Vector Core). Recombinant AAV vectors were 
generated using HEK293 cells grown in serum-free suspen-
sion conditions in WAVE Bioreactors (GE Healthsciences, 
Pittsburgh, PA) as described in Grieger et al. (J.C. Grieger 
and R.J. Samulski, manuscript in preparation).
In brief, the suspension of HEK293 cells were transfected 
using polythyleneimine (Polysciences, Warrington, PA) and 
the following plasmids XX680,49 pXR2,50 pXR2.5,51 with 
scAAV vector plasmids ptrsKS CMV-eGFP,52 and ptrsKS 
CMV-IL1-ra to generate scAAV2 CMV-eGFP, scAAV2 IL-1ra, 
scAAV2.5eGFP, and scAAV2.5 CMV-IL1-ra. Forty-eight hours 
post-transfection, WAVE bioreactor cell cultures were centri-
fuged and supernatant was discarded. The cells were re-sus-
pended and lysed through sonication as described by Grieger 
et al.53 Five hundred and fifty units of DNase was added to the 
lysate and incubated at 37 °C for 45 minutes, followed by 
centrifugation at 9,400g to pellet the cell debris and the clari-
fied lysate was loaded onto a modified discontinuous iodix-
anol gradient followed by ion exchange chromatography.
scAAV2CMVIL-1ra and scAAV2CBhIL-1ra were evaluated 
for protein production and functionality in chondrocytes and 
synoviocytes. Mature equine chondrocytes and synoviocytes 
were harvested from cadaveric stifle joints as previously 
described.54 Chondrocytes were used immediately; syn-
oviocytes were used after three subsequent passages. Cells 
were plated to 60% confluency and equilibrated for 48 hours 
in Ham’s F12 media (Invitrogen) supplemented as described 
above. Cells were transduced with 8,000 viral particles per 
cell in nonsupplemented F12. Supplemented medium was 
replaced after 3 hours and cells were cultured for an additional 
4 days. Once equilibrated, cells were stimulated with 10 ng/
ml of recombinant equine IL-1β (R&D Systems) for 48 hours. 
Media was collected and evaluated with a mouse IL1-ra kit 
(R&D Systems) and PGE2 kit (Enzo Life Sciences, Farm-
ingdale, NY).
Clinical trial. All animal work was approved by Colorado State 
University Institutional Animal Care and Use Committee. An 
initial pilot study consisting of two skeletally mature horses 
was performed over a 6-month period to assess dosing and 
serotype administration. Both fore metacarpophalangeal and 
mid-carpal joints were dosed with either saline, scAAVGFP 
or scAAVIL-1ra viral constructs. The scAAV constructs were 
either serotype 2 or 2.5, and were given at two different 
dose concentrations (5 × 1013 and 5 × 1012 viral particles). 
Lameness and physical examinations, serum and synovial 
fluid samples were collected at day 0 to establish baseline 
levels. Serum and synovial fluid samples were collected 2 
weeks post-injection and every other week thereafter for 3 
or 28 weeks. Samples were then collected every other week 
until day 23 for Horse 2 (horse used for short-term study) 
and week 28 for Horse 1 (horse used for long-term study), at 
which time the animals were euthanized and tissue samples 
were collected for histology, biodistribution, and functional 
assays.
Arthroscopic examination. Arthroscopic assessment was per-
formed on the carpal joints of Horse 1 at 28 weeks following 
euthanasia. Fluorescent filters on the arthroscope were used 
to evaluate synovial joint capsule and cartilage for fluoresc-
ing cells. Since one carpal joint had scAAVGFP injected and 
the contralateral joint had scAAVEq-opt-IL-1ra injected, the 
joints acted as a positive and negative control, respectively. 
Fluorescence was imaged and video recorded.
Serum and synovial fluid evaluation and viral biodistribution. 
Serum samples were evaluated for circulating levels of IL1-ra 
with an equine IL1-ra ELISA (R&D Systems). Synovial fluid 
samples were evaluated for total protein and fluid cytology, 
as well as IL1-ra with the same previously mentioned ELISA 
kit. Serum samples were diluted 1:20 and synovial fluid sam-
ples were diluted 1:40 in reagent diluent (1% bovine serum 
albumin in phosphate-buffered saline) before IL-1ra evalua-
tion. Once diluted, samples were evaluated per manufacturer 
instructions.
Synovial fluid samples were also assessed for their functional 
ability against IL-1β stimulation in synovial monolayer cultures. 
We first established that the synovial fluid alone would have 
minimal effects on the IL-1β response in stimulated monolayer 
culture samples. Non-osteoarthritic equine synovial fluid sam-
ples (from nonstudy horses), with non-detectable levels of IL-
1ra, were added to synoviocytes at vol/vol concentrations of 10, 
25, and 50% synovial fluid simultaneously with equine rIL-1β 
supplemented media (10 ng rIL1β per ml; R&D Systems). Media 
was collected after 48 hours and evaluated for IL-1β levels with 
a commercially available equine IL-1β ELISA kit (King Biofisher, 
St Paul, MN). To assess the harvested synovial fluids from the 
study animals, synovial fluids from injected joints were added 
to synoviocytes at 50% vol/vol concentrations of synovial fluid 
simultaneously with equine rIL-1β supplemented media. The 
amount of IL-1ra present in each synovial fluid sample ranged 
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from non-detectable to ~1 μg per ml. Media was collected after 
48 hours and evaluated as described above.
Tissue samples were collected from each animal at necropsy 
to assess the biodistribution of IL-1ra viral particles. Quantita-
tive PCR was used for vector genome biodistribution studies. 
Tissue DNA was purified and quantified using SyBR Green as 
described.55 Data is reported as the number of double-stranded 
IL1-ra vector DNA molecules per two copies of the equine 
GAPDH locus, or in other words the number of vector DNA 
copies per diploid equine genome. The equine GAPDH prim-
ers are as follows: forward 5′-GATTGTCAGCAATGCCTCCT; 
reverse 5′-TGCCAAAGTGGTCATGGAT. The IL-1ra primers 
are as follows: forward 5′-AGCTTCCCGGCAACAATTA; 
reverse 5′-GCAGAAGTGGTCCTGCAACT.
Histology and explant evaluation. Tissue samples taken 
from the forelimb carpal and metacarpal phalangeal joints 
from each horse were visualized with a fluorescent micro-
scope. Images were captured under ×100 magnification, 
with a FITC fluorescent filter cube with an excitation of 495 
nm and emission of 521 nm. Synovium and osteochondral 
sections were placed into formalin. Osteochondral samples 
were decalcified using an EDTA-based decalcification solu-
tion. All samples were paraffin embedded and mounted onto 
charged slides. All tissues were deparaffinized and stained 
with hematoxylin and eosin. Samples were rehydrated with 
a series of ethanol incubations, followed by hematoxylin 
stain, blue buffer solution and eosin counterstaining. Slides 
were rinsed with dH
2O between each stain. Subchondral 
bone fragments were also stained with Alcian blue. Sam-
ples were deparaffinized and rehydrated as described, and 
were incubated in 3% acetic acid, Alcian blue, and nuclear 
fast red counterstain. Slides were rinsed between stains as 
described. Slides were dehydrated and cover slipped for 
analysis. Histological sections were observed and scored 
for inflammation, sclerosis (synovium), matrix degeneration, 
and surface defects (cartilage).
supplementary Material
Video s1.
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